Correlation Engine 2.0
Clear Search sequence regions


  • ABC (2)
  • abc transporters (1)
  • ABCB1 (79)
  • ABCG2 (103)
  • acid (1)
  • amyloid (1)
  • anesthesia (1)
  • anti- igg (1)
  • APP (38)
  • APP 1 (1)
  • at last time (1)
  • austria (1)
  • basement membrane (1)
  • blood (5)
  • blood- brain barrier (20)
  • brain (95)
  • brain 1 (1)
  • brain 4 (1)
  • brain metastases (1)
  • breast cancer (2)
  • cancer (1)
  • catheter (1)
  • cerebellum (9)
  • china (1)
  • curves (4)
  • dark (1)
  • data analysis (1)
  • diet (1)
  • digoxin (2)
  • drug treatment (1)
  • EGFR (1)
  • erlotinib (28)
  • ethanol (2)
  • finland (1)
  • frozen sections (1)
  • hippocampus (10)
  • human (5)
  • hydrogen (1)
  • interest (1)
  • knockout mice (2)
  • light (1)
  • measure (6)
  • membrane cells (1)
  • methanol (1)
  • mice (62)
  • microvessels (9)
  • nickel (1)
  • nitrogen (1)
  • non small cell lung cancer (1)
  • p glycoprotein (2)
  • patients (8)
  • peptides (5)
  • period (3)
  • pet protocol (3)
  • pet scans (14)
  • plasma (7)
  • positron (44)
  • protocol (2)
  • PS1 (38)
  • receptor (1)
  • rodent (1)
  • signals (1)
  • slides (8)
  • stain (1)
  • strains (6)
  • suggest (4)
  • switzerland (2)
  • tariquidar (39)
  • tau protein (1)
  • Thy1 (1)
  • too (1)
  • tris (3)
  • tween 80 (1)
  • verapamil (5)
  • visual fields (1)
  • weight (4)
  • western blot (4)
  • Sizes of these terms reflect their relevance to your search.

    ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) are co-localized at the blood-brain barrier (BBB), where they restrict the brain distribution of many different drugs. Moreover, ABCB1 and possibly ABCG2 play a role in Alzheimer's disease (AD) by mediating the brain clearance of beta-amyloid (Aβ) across the BBB. This study aimed to compare the abundance and activity of ABCG2 in a commonly used β-amyloidosis mouse model (APP/PS1-21) with age-matched wild-type mice. The abundance of ABCG2 was assessed by semi-quantitative immunohistochemical analysis of brain slices of APP/PS1-21 and wild-type mice aged 6 months. Moreover, the brain distribution of two dual ABCB1/ABCG2 substrate radiotracers ([11C]tariquidar and [11C]erlotinib) was assessed in APP/PS1-21 and wild-type mice with positron emission tomography (PET). [11C]Tariquidar PET scans were performed without and with partial inhibition of ABCG2 with Ko143, while [11C]erlotinib PET scans were only performed under baseline conditions. Immunohistochemical analysis revealed a significant reduction (by 29-37%) in the number of ABCG2-stained microvessels in the brains of APP/PS1-21 mice. Partial ABCG2 inhibition significantly increased the brain distribution of [11C]tariquidar in APP/PS1-21 and wild-type mice, but the brain distribution of [11C]tariquidar did not differ under both conditions between the two mouse strains. Similar results were obtained with [11C]erlotinib. Despite a reduction in the abundance of cerebral ABCG2 and ABCB1 in APP/PS1-21 mice, the brain distribution of two dual ABCB1/ABCG2 substrates was unaltered. Our results suggest that the brain distribution of clinically used ABCB1/ABCG2 substrate drugs may not differ between AD patients and healthy people.

    Citation

    Thomas Wanek, Viktoria Zoufal, Mirjam Brackhan, Markus Krohn, Severin Mairinger, Thomas Filip, Michael Sauberer, Johann Stanek, Thomas Pekar, Jens Pahnke, Oliver Langer. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model. International journal of molecular sciences. 2020 Nov 03;21(21)

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33153231

    View Full Text